SightfileU.S. market data from official filings

Companies › KAPA

KAIROS PHARMA LTD (KAPA)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001962011 · EDGAR filings · Updated 2026-07-22

KAIROS PHARMA LTD (KAPA) has reported institutional ownership of 2.8%, with 11 institutional managers holding positions valued at $341.5K per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Institutional ownership
2.8%
Institutional managers
11
Reported 13F value
$341.5K
Insider activity
10 trans.
$0 net flat
Data flags
1 active
from SEC filings

Filings this week (1)

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, KAIROS PHARMA LTD has 11 institutional holders and institutional ownership of 2.8%.

Insider activity

Insiders reported 10 transactions (0 buys, 0 sells) across 7 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-05-13 (recurring since 2024-11-14) — source filing. The authoritative details are those stated in the filing itself.

Related companies

ALAUNOS THERAPEUTICS INC (TCRT) · CNS PHARMACEUTICALS INC (CNSP) · MOLECULIN BIOTECH INC (MBRX) · NexGel Inc (NXGL) · Soligenix Inc (SNGX) · Akari Therapeutics PLC ADR (AKTX)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-22.